Current Management of Relapsed Acute Myeloid Leukemia
Slideset - In this downloadable slideset, Gail J. Roboz, MD, explores optimal treatment approaches for patients with relapsed/refractory acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 13, 2017 Category: Hematology Source Type: research
Managing Newly Diagnosed AML: Treatment Considerations to Personalize Care: Downloadable Slides
Slideset - In this downloadable slideset, Jeffrey E. Lancet, MD, explores current strategies for treating patients with newly diagnosed acute myeloid leukemia based on patient medical history and cytogenetic and molecular markers. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 13, 2017 Category: Hematology Source Type: research
Midostaurin Maintenance After Midostaurin Plus Chemotherapy in FLT3-Mutated AML: Post Hoc Analysis in RATIFY
Slideset - No clear evidence of benefit associated with midostaurin maintenance therapy in this unplanned post hoc subset analysis of the RATIFY trial. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 13, 2017 Category: Hematology Source Type: research
Interim Report: Inotuzumab Ozogamicin + Bosutinib in R/R Ph+ ALL or CML in Lymphoid Blast Phase
Slideset - Review promising preliminary findings from a phase I/II trial assessing combination therapy with inotuzumab ozogamicin and bosutinib in patients with relapsed/refractory Philadelphia chromosome –positive ALL or CML in lymphoid blast phase. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 12, 2017 Category: Hematology Source Type: research
Expanding the Information Needed to Make the Most Informed Treatment Decisions in AML: Downloadable Slides
Slideset - In this downloadable slideset, B. Douglas Smith, MD, explores current strategies for diagnosing and treating patients with acute myeloid leukemia based on patient medical history and cytogenetic and molecular markers. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 12, 2017 Category: Hematology Source Type: research
HCL-PG03: Phase II Trial of Vemurafenib + Rituximab in Patients With Relapsed/Refractory Hairy Cell Leukemia
Slideset - A CR was achieved in 100% of patients with R/R HCL treated with the chemotherapy-free combination of vemurafenib plus rituximab. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 11, 2017 Category: Hematology Source Type: research
Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients: Diagnostic Testing Guide
PDF - Download this guide for a quick overview of current approaches in the use of molecular analysis to individualize treatment strategies in patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 7, 2017 Category: Hematology Source Type: research
Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients: Clinical Trial Guide
PDF - Download this guide for a quick overview of phase III multicenter clinical trials in acute myeloid leukemia currently recruiting patients to find a study that may offer your patient an opportunity for the latest individualized treatment in AML. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 5, 2017 Category: Hematology Source Type: research
My Top Picks for AML Abstracts in Atlanta
Discussion - What are some of the most clinically important AML abstracts to watch for at ASH this year? Read on for a few expert selections. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - November 20, 2017 Category: Hematology Source Type: research
How I Use New Targeted Agents to Improve Outcomes for My Patients With AML
Discussion - Here are my thoughts on how best to apply the recently approved targeted agents gemtuzumab ozogamicin, midostaurin, and enasidenib to improve outcomes for your patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - October 12, 2017 Category: Hematology Source Type: research
How Newly Approved CPX-351 Will Change AML Treatment
Discussion - CPX-351 is beginning to replace traditional 3+7 chemotherapy for secondary or high-risk AML. Learn what you need to know to use it effectively in the clinic. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - September 27, 2017 Category: Hematology Source Type: research
CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory < i > FLT3 < /i > -ITD AML
Slideset - Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 14, 2017 Category: Hematology Source Type: research
Phase I Trial of CD19-Targeted 19-28z CAR T-Cell Therapy in Adult Pts With R/R B-Cell ALL
Slideset - Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - June 12, 2017 Category: Hematology Source Type: research
